Scholar Rock Holding Corp (SRRK)

$35.48 -0.33 (-0.92%)
Market Cap 3.40B
Revenue (ttm) 0.00
Net Income (ttm) -246.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.16
Volume 848,900
Avg Vol 1,292,042
Day's Range N/A - N/A
Shares Out 94.95M
Stochastic %K 75%
Beta 0.28
Analysts Strong Sell
Price Target $47.67

Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively targ...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 259 3860
Address:
301 Binney Street, 3rd Floor, Cambridge, United States
Quantumup
Quantumup Jun. 26 at 1:06 PM
Truist reiterated $SRRK Buy-$45 and said, "We hosted a conference call with neurologist Dr. Dusan Roncevic on the potential of apitegromab in SMA." $BHVN $LLY REGN RHHBY $BIIB $NVS Truist additionally said, "KOL noted that apitegromab has potential to address the unmet need of muscle decline which is seen across patients. Data from SAPPHIRE trial is clinically meaningful and supports apitegromab as a combo agent with different approved SMA therapies, as per KOL. He believes the data support a broad label (across ages & ambulatory status) and expects to use drug broadly irrespective of label as long as there are no reimbursement challenges. Broad uptake would be an upside to our estimates given we currently model uptake only in non-ambulatory patients. Reiterate Buy."
0 · Reply
Quantumup
Quantumup Jun. 25 at 6:32 PM
BTIG reiterated $VKTX Buy-$125 and said "Today, Viking Therapeutics announced the initiation of their Two Phase 3 Obesity VANQUISH studies with VK2735." $LLY $GPCR NVO $SRRK $TERN ALT PFE AMGN BTIG added, "We are encouraged by Viking's execution and progress across their obesity franchise and continue to see tremendous value in the company's potentially best-in-class portfolio of obesity and metabolic disease programs." BTIG went on to say:
0 · Reply
green_going_up
green_going_up Jun. 24 at 10:18 PM
$VERU has great muscle preserving data; the FDA, for whatever reason, is currently dismissing muscle retention; everyone in the world knows muscle burns more than fat; quality weight loss is imperative; it's like nobody in the FDA in weight loss ever went to the gym. Let's hope with similar focus on quality weight loss by other firms such as $REGN, $SRRK, etc, that the FDA can get their heads out of their arses.
1 · Reply
Chomo
Chomo Jun. 23 at 2:11 PM
$SRRK this is what you dont wanna see after a massive breakout on 5X volume on thursday...
0 · Reply
Polip
Polip Jun. 20 at 7:13 PM
$SRRK gap fill at 10 or BO at 50
0 · Reply
Sillyspuh
Sillyspuh Jun. 20 at 4:38 PM
$SRRK Why the big drop?
0 · Reply
Quantumup
Quantumup Jun. 20 at 12:22 PM
H.C. Wainwright reit'd $SRRK Buy-$50 after $SRRK recently announced highly compelling top line results from its Phase 2 EMBRAZE trial, reinforcing the clinical pot'l of apitegromab when used in combo w/ tirzepatide in obese and OW pts. $LLY $BHVN $RHHBY $BIIB NVS HCW said in its note:
1 · Reply
ValuePlayRunners
ValuePlayRunners Jun. 18 at 11:31 PM
$SRRK $ALT has the better all around drug comparatively and better discounted value at least right now. MASH inbound. Lean preservation with pemi already solid 21% and probably drop even more with longer time periods. Also why take two drugs when there will be "1" that does it all - weight loss, lean pres, MASH/NASH, lipids/trigs/chol and much more. ALT will be BO soon if MASH data excels.
1 · Reply
LewisDaKat
LewisDaKat Jun. 18 at 7:25 PM
News Why Scholar Rock Shares Are Soaring Today https://marketwirenews.com/news-releases/why-scholar-rock-shares-are-soaring-today-5800030031004867.html $SRRK
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 18 at 6:31 PM
Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss $SRRK $REGN $VTI https://stocktwits.com/news/equity/markets/scholar-rock-stock-soars-after-investigational-drug-helps-preserve-lean-mass/chlsXcSRR2k
0 · Reply
Latest News on SRRK
Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

Jun 24, 2025, 6:25 PM EDT - 2 days ago

Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

Jun 23, 2025, 8:00 AM EDT - 3 days ago

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

Jun 18, 2025, 10:47 AM EDT - 8 days ago

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

LLY

Scholar Rock Shares Jump on Positive Results from Weight Loss Trial

Jun 18, 2025, 7:33 AM EDT - 8 days ago

Scholar Rock Shares Jump on Positive Results from Weight Loss Trial

Scholar Rock's drug helps preserve lean mass in mid-stage trial

Jun 18, 2025, 7:12 AM EDT - 8 days ago

Scholar Rock's drug helps preserve lean mass in mid-stage trial

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

Jun 18, 2025, 7:00 AM EDT - 8 days ago

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 13, 2025, 4:15 PM EDT - 13 days ago

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 21 days ago

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

Jun 2, 2025, 8:00 AM EDT - 24 days ago

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

Scholar Rock to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 4 weeks ago

Scholar Rock to Present at the Jefferies Global Healthcare Conference

Scholar Rock Holding Corporation (SRRK) Q1 2025 Earnings Call Transcript

May 14, 2025, 12:30 PM EDT - 6 weeks ago

Scholar Rock Holding Corporation (SRRK) Q1 2025 Earnings Call Transcript

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

May 14, 2025, 7:00 AM EDT - 6 weeks ago

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

May 7, 2025, 8:00 AM EDT - 7 weeks ago

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth

Apr 28, 2025, 6:50 AM EDT - 2 months ago

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Mar 25, 2025, 7:30 AM EDT - 3 months ago

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment

Mar 17, 2025, 12:21 PM EDT - 3 months ago

Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Mar 16, 2025, 7:00 PM EDT - 3 months ago

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 1:23 PM EST - 4 months ago

Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Feb 27, 2025, 7:00 AM EST - 4 months ago

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Scholar Rock to Participate in Upcoming Investor Conferences

Feb 25, 2025, 4:15 PM EST - 4 months ago

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 21, 2025, 8:00 AM EST - 4 months ago

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

Feb 19, 2025, 10:41 AM EST - 4 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN KROS LLY NVO REGN

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Feb 10, 2025, 8:00 AM EST - 4 months ago

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

Jan 30, 2025, 8:37 AM EST - 5 months ago

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Jan 29, 2025, 8:05 AM EST - 5 months ago

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Jan 29, 2025, 8:00 AM EST - 5 months ago

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth

Jan 15, 2025, 2:23 PM EST - 5 months ago

Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth

Scholar Rock Highlights 2025 Strategic Priorities

Jan 8, 2025, 4:00 PM EST - 6 months ago

Scholar Rock Highlights 2025 Strategic Priorities

Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 8:00 AM EST - 6 months ago

Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

Nov 25, 2024, 11:51 AM EST - 7 months ago

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 11:09 AM EST - 8 months ago

Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call Transcript

Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress

Nov 12, 2024, 7:00 AM EST - 8 months ago

Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress

Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin

Nov 4, 2024, 8:00 AM EST - 8 months ago

Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Nov 1, 2024, 8:00 AM EDT - 8 months ago

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting

Oct 31, 2024, 8:00 AM EDT - 8 months ago

Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

Oct 25, 2024, 8:22 AM EDT - 8 months ago

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

IBRX

Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering

Oct 22, 2024, 8:00 AM EDT - 8 months ago

Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering

Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants

Oct 8, 2024, 11:08 PM EDT - 9 months ago

Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants

Scholar Rock (SRRK) Shares Surge on Successful SMA Drug Trial

Oct 7, 2024, 10:10 PM EDT - 9 months ago

Scholar Rock (SRRK) Shares Surge on Successful SMA Drug Trial

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Oct 7, 2024, 5:29 PM EDT - 9 months ago

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Oct 7, 2024, 4:09 PM EDT - 9 months ago

Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Dow Jones, S&P 500 fall amid rising oil prices; Scholar Rock jumps 300%, Apple and insurance stocks dip

Oct 7, 2024, 3:28 PM EDT - 9 months ago

Dow Jones, S&P 500 fall amid rising oil prices; Scholar Rock jumps 300%, Apple and insurance stocks dip

Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher

Oct 7, 2024, 12:00 PM EDT - 9 months ago

Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher

Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year

Oct 7, 2024, 10:23 AM EDT - 9 months ago

Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year

Scholar Rock's stock soars more than 200% on positive trial of treatment for spinal muscular atrophy

Oct 7, 2024, 8:20 AM EDT - 9 months ago

Scholar Rock's stock soars more than 200% on positive trial of treatment for spinal muscular atrophy

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)

Oct 7, 2024, 7:00 AM EDT - 9 months ago

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)

Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

Sep 10, 2024, 8:00 AM EDT - 10 months ago

Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Sep 4, 2024, 8:00 AM EDT - 10 months ago

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 10 months ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP GPCR VKTX

Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress

Aug 8, 2024, 7:00 AM EDT - 11 months ago

Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress

Quantumup
Quantumup Jun. 26 at 1:06 PM
Truist reiterated $SRRK Buy-$45 and said, "We hosted a conference call with neurologist Dr. Dusan Roncevic on the potential of apitegromab in SMA." $BHVN $LLY REGN RHHBY $BIIB $NVS Truist additionally said, "KOL noted that apitegromab has potential to address the unmet need of muscle decline which is seen across patients. Data from SAPPHIRE trial is clinically meaningful and supports apitegromab as a combo agent with different approved SMA therapies, as per KOL. He believes the data support a broad label (across ages & ambulatory status) and expects to use drug broadly irrespective of label as long as there are no reimbursement challenges. Broad uptake would be an upside to our estimates given we currently model uptake only in non-ambulatory patients. Reiterate Buy."
0 · Reply
Quantumup
Quantumup Jun. 25 at 6:32 PM
BTIG reiterated $VKTX Buy-$125 and said "Today, Viking Therapeutics announced the initiation of their Two Phase 3 Obesity VANQUISH studies with VK2735." $LLY $GPCR NVO $SRRK $TERN ALT PFE AMGN BTIG added, "We are encouraged by Viking's execution and progress across their obesity franchise and continue to see tremendous value in the company's potentially best-in-class portfolio of obesity and metabolic disease programs." BTIG went on to say:
0 · Reply
green_going_up
green_going_up Jun. 24 at 10:18 PM
$VERU has great muscle preserving data; the FDA, for whatever reason, is currently dismissing muscle retention; everyone in the world knows muscle burns more than fat; quality weight loss is imperative; it's like nobody in the FDA in weight loss ever went to the gym. Let's hope with similar focus on quality weight loss by other firms such as $REGN, $SRRK, etc, that the FDA can get their heads out of their arses.
1 · Reply
Chomo
Chomo Jun. 23 at 2:11 PM
$SRRK this is what you dont wanna see after a massive breakout on 5X volume on thursday...
0 · Reply
Polip
Polip Jun. 20 at 7:13 PM
$SRRK gap fill at 10 or BO at 50
0 · Reply
Sillyspuh
Sillyspuh Jun. 20 at 4:38 PM
$SRRK Why the big drop?
0 · Reply
Quantumup
Quantumup Jun. 20 at 12:22 PM
H.C. Wainwright reit'd $SRRK Buy-$50 after $SRRK recently announced highly compelling top line results from its Phase 2 EMBRAZE trial, reinforcing the clinical pot'l of apitegromab when used in combo w/ tirzepatide in obese and OW pts. $LLY $BHVN $RHHBY $BIIB NVS HCW said in its note:
1 · Reply
ValuePlayRunners
ValuePlayRunners Jun. 18 at 11:31 PM
$SRRK $ALT has the better all around drug comparatively and better discounted value at least right now. MASH inbound. Lean preservation with pemi already solid 21% and probably drop even more with longer time periods. Also why take two drugs when there will be "1" that does it all - weight loss, lean pres, MASH/NASH, lipids/trigs/chol and much more. ALT will be BO soon if MASH data excels.
1 · Reply
LewisDaKat
LewisDaKat Jun. 18 at 7:25 PM
News Why Scholar Rock Shares Are Soaring Today https://marketwirenews.com/news-releases/why-scholar-rock-shares-are-soaring-today-5800030031004867.html $SRRK
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 18 at 6:31 PM
Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss $SRRK $REGN $VTI https://stocktwits.com/news/equity/markets/scholar-rock-stock-soars-after-investigational-drug-helps-preserve-lean-mass/chlsXcSRR2k
0 · Reply
MicroCapV1k1ng
MicroCapV1k1ng Jun. 18 at 5:58 PM
$SRRK
0 · Reply
AlexTrades2
AlexTrades2 Jun. 18 at 5:53 PM
$SRRK GLP-1 read out using apitegromab to help with lean mass preservation so patients don’t get flabby . Looking good so far https://stocks.apple.com/AmzgO89BLT9WVDmqsEORvVA
0 · Reply
jParkz
jParkz Jun. 18 at 3:31 PM
News out Scholar Rock Holding Corp. (NASDAQ: SRRK) Rises Sharply in 6/18 Early Trading Session https://marketwirenews.com/news-releases/scholar-rock-holding-corp-nasdaq-srrk-rises-sharply--8713072929588617.html $SRRK
0 · Reply
cheating_stock_investor
cheating_stock_investor Jun. 18 at 2:38 PM
$SRRK
0 · Reply
cheating_stock_investor
cheating_stock_investor Jun. 18 at 2:38 PM
$SRRK still good here.
0 · Reply
Racetothetop
Racetothetop Jun. 18 at 2:34 PM
$SRRK 👏 👏
0 · Reply
topstockalerts
topstockalerts Jun. 18 at 2:14 PM
$SRRK she wants to move higher..🚨💪🚨
0 · Reply
WolverineVcapitalllc
WolverineVcapitalllc Jun. 18 at 2:08 PM
$CRCL $SRRK
0 · Reply
DonCorleone77
DonCorleone77 Jun. 18 at 1:18 PM
$ACB $RBNE $SRRK $ESEA $PRE Feel free to follow me for pre-market and after-hours movers every day. PRE-MARKET MOVERS: Currently Higher After Earnings: -- Korn Ferry (KFY) up 12.3% -- Euroseas (ESEA) up 8.7% -- GMS Inc. (GMS) up 12.6% Currently Also Higher: -- Circle (CRCL) up 2.9% after Senate passes bill to set up stablecoin framework -- Scholar Rock (SRRK) up 6.3% after announcing results from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss -- Prenetics (PRE) up 5.2% after announcing it will divest ACT Genomics to Delta Electronics in $71.78M transaction as well as raising FY24 revenue view Currently LowerAfter Earnings: -- Aurora Cannabis (ACB) down 11.6% Currently Also Lower: -- Robin Energy (RBNE) down 23.8% after pricing 860,000 shares at $5.25 in registered direct offering
0 · Reply
NolAsrtormZ
NolAsrtormZ Jun. 18 at 1:10 PM
$SRRK its like they forgot to release 100% of data and cherry picked
0 · Reply
NolAsrtormZ
NolAsrtormZ Jun. 18 at 1:10 PM
$SRRK The fade is real 🤣
0 · Reply
TheDizPlinTrader
TheDizPlinTrader Jun. 18 at 1:04 PM
$SRRK 1H Levels Price: $32.79 Support: $31.81 Resistance: $33.77 Trend remains solid — bulls holding breakout zone.
0 · Reply